Fisetin

The reviewed human records concern specific bone and biomarker outcomes. The size of the trial arm, the comparison and adverse events matter alongside the hypothesis.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: Fisetin has demonstrated broad anti-aging benefits in people.

What the reviewed records say:

The gap: Small study arms and limited endpoints do not establish broad benefit or long-term safety.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

Small study arms and limited endpoints do not establish broad benefit or long-term safety.